Toronto, Ontario--(Newsfile Corp. - Le 19 août/August 2024) - Aduro Clean Technologies Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every three and one quarter (3.25) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 27,174,297 common shares. The name and symbol will not change. Please note that all open orders will be canceled at the close of ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:GormanRupp (GRC) : This company which designs, manufactures and sells pumps and related equipment, has seen the Zacks Consensus Estimate for its current year earnings increasing 11.5% over the last 60 days.Hagerty (HGTY) : This company which offer automotive lifestyle brand and specialty insurance provider focused on automotive enthusiast market, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.5% over th ...

Enact Holdings, Inc. (NASDAQ:ACT) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Daniel Kohl - VP, Investor Relations Rohit Gupta - President, Chief Executive Officer and Director Dean Mitchell - Executive Vice President, Chief Financial Officer, and Treasurer Conference Call Participants Soham Bhonsle - BTIG Rick Shane - JPMorgan Mihir Bhatia - Bank of America Geoffrey Dunn - Dowling Operator Good day, and thank you for standing by. Welcome to the Enact’s Q2 2024 Earnings C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40399 Enact Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

-       Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs-       Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined immunodeficiency disease, β-thalassemia and Fanconi's anemiaNEW YORK, Aug. 1, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or ...

Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.30%. A quarter ago, it was expected that this company would post earnings of $0.99 per share when it actually produced earnings of $1.04, delivering a surprise of 5.05%.Over the last four quarters, the compa ...

Exhibit 99.1 ENACT REPORTS SECOND QUARTER 2024 RESULTS AND ANNOUNCES QUARTERLY DIVIDEND _______________________________________ GAAP Net Income of $184 million, or $1.16 per diluted share Adjusted Operating Income of $201 million, or $1.27 per diluted share Return on Equity of 15.4% and Adjusted Operating Return on Equity of 16.9% Record Primary insurance in-force of $266 billion, a 3% increase from second quarter 2023 PMIERs Sufficiency of 169% or $2,057 million Book Value Per Share of $30.91 and Book Valu ...

GAAP Net Income of $184 million, or $1.16 per diluted shareAdjusted Operating Income of $201 million, or $1.27 per diluted shareReturn on Equity of 15.4% and Adjusted Operating Return on Equity of 16.9%Record Primary insurance in-force of $266 billion, a 3% increase from second quarter 2023PMIERs Sufficiency of 169% or $2,057 millionBook Value Per Share of $30.91 and Book Value Per Share excluding AOCI of $32.43Announces quarterly cash dividend of $0.185 per common share RALEIGH, N.C., July 31, 2024 (GLOBE ...

- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need- Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease patients- Initial trial focused on conditioning for bone marrow transplant intended to inform subsequent gene therapy conditioning study and provide broader access to ce ...

tattywelshie/E+ via Getty Images One of the most eye-watering charts I've seen in a while is the one showing the rise in median prices of homes in the United States over the last ten years, recently touching nearly $435,000. As a parent of children not far off from being on their own, I can certainly sympathize with the frustrations of those who are priced out of the housing market, and I confess that I wonder about whether my children will be able to buy their own homes. Median home price, 2014 - 202 ...